In vivo absorption of aluminium-containing vaccine adjuvants using 26Al

Richard E. Flarend, Stanley L. Hem, Joe L. White, David Elmore, Mark A. Suckow, Anita C. Rudy, Euphemie A. Dandashli

Research output: Contribution to journalArticle

132 Citations (Scopus)

Abstract

Aluminium hydroxide (AH) and aluminium phosphate (AP) adjuvants, labelled with 26Al, were injected intramuscularly (i.m.) in New Zealand White rabbits. Blood and urine samples were collected for 28 days and analysed for 26Al using accelerator mass spectrometry to determine the absorption and elimination of AH and AP adjuvants. 26Al was present in the first blood sample (1 h) for both adjuvants. The area under the blood level curve for 28 days indicates that three times more aluminium was absorbed from AP adjuvant than AH adjuvant. The distribution profile of aluminium to tissues was the same for both adjuvants (kidney > spleen > liver > heart > lymph node > brain). This study has demonstrated that in vivo mechanisms are available to eliminate aluminium-containing adjuvants after i.m. administration. In addition, the pharmacokinetic profiles of AH and AP adjuvants are different.

Original languageEnglish (US)
Pages (from-to)1314-1318
Number of pages5
JournalVaccine
Volume15
Issue number12-13
DOIs
StatePublished - Aug 1 1997

Fingerprint

Aluminum Hydroxide
vaccine adjuvants
Aluminum
adjuvants
aluminum
Vaccines
aluminum phosphate
aluminum hydroxide
Mass Spectrometry
blood
Spleen
Pharmacokinetics
Lymph Nodes
Urine
Rabbits
Kidney
New Zealand White rabbit
Liver
Brain
pharmacokinetics

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Cite this

Flarend, R. E., Hem, S. L., White, J. L., Elmore, D., Suckow, M. A., Rudy, A. C., & Dandashli, E. A. (1997). In vivo absorption of aluminium-containing vaccine adjuvants using 26Al. Vaccine, 15(12-13), 1314-1318. https://doi.org/10.1016/S0264-410X(97)00041-8
Flarend, Richard E. ; Hem, Stanley L. ; White, Joe L. ; Elmore, David ; Suckow, Mark A. ; Rudy, Anita C. ; Dandashli, Euphemie A. / In vivo absorption of aluminium-containing vaccine adjuvants using 26Al. In: Vaccine. 1997 ; Vol. 15, No. 12-13. pp. 1314-1318.
@article{ed6f3883159649e88e30a1ecc1ac0885,
title = "In vivo absorption of aluminium-containing vaccine adjuvants using 26Al",
abstract = "Aluminium hydroxide (AH) and aluminium phosphate (AP) adjuvants, labelled with 26Al, were injected intramuscularly (i.m.) in New Zealand White rabbits. Blood and urine samples were collected for 28 days and analysed for 26Al using accelerator mass spectrometry to determine the absorption and elimination of AH and AP adjuvants. 26Al was present in the first blood sample (1 h) for both adjuvants. The area under the blood level curve for 28 days indicates that three times more aluminium was absorbed from AP adjuvant than AH adjuvant. The distribution profile of aluminium to tissues was the same for both adjuvants (kidney > spleen > liver > heart > lymph node > brain). This study has demonstrated that in vivo mechanisms are available to eliminate aluminium-containing adjuvants after i.m. administration. In addition, the pharmacokinetic profiles of AH and AP adjuvants are different.",
author = "Flarend, {Richard E.} and Hem, {Stanley L.} and White, {Joe L.} and David Elmore and Suckow, {Mark A.} and Rudy, {Anita C.} and Dandashli, {Euphemie A.}",
year = "1997",
month = "8",
day = "1",
doi = "10.1016/S0264-410X(97)00041-8",
language = "English (US)",
volume = "15",
pages = "1314--1318",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "12-13",

}

Flarend, RE, Hem, SL, White, JL, Elmore, D, Suckow, MA, Rudy, AC & Dandashli, EA 1997, 'In vivo absorption of aluminium-containing vaccine adjuvants using 26Al', Vaccine, vol. 15, no. 12-13, pp. 1314-1318. https://doi.org/10.1016/S0264-410X(97)00041-8

In vivo absorption of aluminium-containing vaccine adjuvants using 26Al. / Flarend, Richard E.; Hem, Stanley L.; White, Joe L.; Elmore, David; Suckow, Mark A.; Rudy, Anita C.; Dandashli, Euphemie A.

In: Vaccine, Vol. 15, No. 12-13, 01.08.1997, p. 1314-1318.

Research output: Contribution to journalArticle

TY - JOUR

T1 - In vivo absorption of aluminium-containing vaccine adjuvants using 26Al

AU - Flarend, Richard E.

AU - Hem, Stanley L.

AU - White, Joe L.

AU - Elmore, David

AU - Suckow, Mark A.

AU - Rudy, Anita C.

AU - Dandashli, Euphemie A.

PY - 1997/8/1

Y1 - 1997/8/1

N2 - Aluminium hydroxide (AH) and aluminium phosphate (AP) adjuvants, labelled with 26Al, were injected intramuscularly (i.m.) in New Zealand White rabbits. Blood and urine samples were collected for 28 days and analysed for 26Al using accelerator mass spectrometry to determine the absorption and elimination of AH and AP adjuvants. 26Al was present in the first blood sample (1 h) for both adjuvants. The area under the blood level curve for 28 days indicates that three times more aluminium was absorbed from AP adjuvant than AH adjuvant. The distribution profile of aluminium to tissues was the same for both adjuvants (kidney > spleen > liver > heart > lymph node > brain). This study has demonstrated that in vivo mechanisms are available to eliminate aluminium-containing adjuvants after i.m. administration. In addition, the pharmacokinetic profiles of AH and AP adjuvants are different.

AB - Aluminium hydroxide (AH) and aluminium phosphate (AP) adjuvants, labelled with 26Al, were injected intramuscularly (i.m.) in New Zealand White rabbits. Blood and urine samples were collected for 28 days and analysed for 26Al using accelerator mass spectrometry to determine the absorption and elimination of AH and AP adjuvants. 26Al was present in the first blood sample (1 h) for both adjuvants. The area under the blood level curve for 28 days indicates that three times more aluminium was absorbed from AP adjuvant than AH adjuvant. The distribution profile of aluminium to tissues was the same for both adjuvants (kidney > spleen > liver > heart > lymph node > brain). This study has demonstrated that in vivo mechanisms are available to eliminate aluminium-containing adjuvants after i.m. administration. In addition, the pharmacokinetic profiles of AH and AP adjuvants are different.

UR - http://www.scopus.com/inward/record.url?scp=0030986498&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030986498&partnerID=8YFLogxK

U2 - 10.1016/S0264-410X(97)00041-8

DO - 10.1016/S0264-410X(97)00041-8

M3 - Article

C2 - 9302736

AN - SCOPUS:0030986498

VL - 15

SP - 1314

EP - 1318

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 12-13

ER -

Flarend RE, Hem SL, White JL, Elmore D, Suckow MA, Rudy AC et al. In vivo absorption of aluminium-containing vaccine adjuvants using 26Al. Vaccine. 1997 Aug 1;15(12-13):1314-1318. https://doi.org/10.1016/S0264-410X(97)00041-8